FAQ

DJ927

Known as: DJ 927, DJ-927 
A semi-synthetic orally-available taxane derivative with potent antineoplastic properties. DJ-927 binds to tubulin, promoting microtubule assembly… (More)

Topic mentions per year

Topic mentions per year

2003-2008
02420032008

Related topics

Related topics

1 relation

Broader (1)

tesetaxel

Related mentions per year

Related mentions per year

2003-2017
20002005201020152020
DJ927
tesetaxel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer.
INTRODUCTION A phase I/II study was performed to assess the efficacy and toxicity of a new oral taxane in patients with recurrent… (More)
Is this relevant?
2006
2006
Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer.
3591 Background: DJ-927, a novel oral tubulin depolymerization inhibitor, causes apoptosis and DNA cell division arrest. It is… (More)
Is this relevant?
2006
2006
A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen.
4081 Background: Most 1st-line combination chemotherapy regimens in pts with advanced GC include 5-FU. Taxanes are also active… (More)
Is this relevant?
2006
2006
A phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of…
17006 Background: For the treatment of NSCLC (1st and 2nd line) effective oral formulations of drugs are currently investigated… (More)
Is this relevant?
2006
2006
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (D), and capecitabine (C) in patients (Pts) with advanced cancers.
2016 Background: DJ-927, an oral microtubule stabilizer, has impressive cytotoxic activity in taxane-resistant tumors and an… (More)
Is this relevant?
Review
2006
Review
2006
Update on tubulin-binding agents.
The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and… (More)
Is this relevant?
2004
2004
Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers.
2028 Background: DJ-927, a novel semi-synthetic taxane and a poor substrate of P-glycoprotein (Pgp), is orally bioavailable and… (More)
Is this relevant?
2004
2004
Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys.
DJ-927, currently undergoing Phase I clinical trial, is a new orally effective taxane with potent antitumor effects. The… (More)
  • figure 2
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.
DJ-927 is a novel taxane, which was selected for high solubility, non-neurotoxicity, oral bioavailability, and potent antitumor… (More)
Is this relevant?